IRONWOOD PHARMACEUTICALS INC (IRWD) Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Ironwood Pharmaceuticals, Inc. NASDAQ:IRWD Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $578.34M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
Ironwood Pharmaceuticals appointed Chief Commercial Officer Tammi Gaskins as CEO and board member, effective January 1, 2027, succeeding retiring CEO Tom McCourt.
McCourt, CEO since 2021 and a 17-year Ironwood veteran, will remain on the Board, providing transition continuity. The Board cited Gaskins' role in returning LINZESS to blockbuster status and her leadership of the apraglutide commercial strategy.
The release also highlighted that the confirmatory STARS-2 Phase 3 trial of apraglutide in short bowel syndrome with intestinal failure is ongoing, a key pipeline catalyst under the incoming leadership.
• 16d ago AI analysis › Press Release
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ironwood Pharmaceuticals announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10 at 10:15 a.m. ET.
A live webcast will be available through the Investors & Media section of Ironwood's website, with a replay posted following the conference.
The release is a routine investor-calendar notice containing no new financial, clinical, or regulatory information about the company.
• 1mo ago AI analysis › Press Release ● Major ⚠ 1
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Ironwood Pharmaceuticals raised its full-year 2026 guidance, projecting LINZESS net sales of $1.15 to $1.20 billion, representing growth of greater than 30% year-over-year.
Total revenue guidance increased to $460-$485 million and adjusted EBITDA to greater than $310 million, supported by Q2 total revenue of $113 million and adjusted EBITDA of $83 million.
The company repaid $200 million of convertible notes with cash on hand, strengthening its balance sheet, while the confirmatory Phase 3 STARS-2 trial for apraglutide is now actively recruiting.
• 2mo ago AI analysis › Press Release
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
Ironwood Pharmaceuticals announced a leadership transition, appointing Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development effective July 20, 2026, succeeding the retiring Dr. Michael Shetzline.
The company confirmed that its confirmatory Phase 3 STARS-2 trial for apraglutide in patients with short bowel syndrome with intestinal failure was initiated in June and is actively recruiting patients.
Dr. Silber joins Ironwood from Vedanta Biosciences and will oversee Research, Drug Development, Regulatory Affairs and Medical Affairs as the company advances its pipeline alongside commercialized LINZESS.
• 3mo ago AI analysis › Press Release
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Ironwood Pharmaceuticals announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference.
The session is scheduled for Thursday, June 4, at 11:05 a.m. ET.
A live webcast and replay will be available on the company’s investor relations website.
• 5mo ago AI analysis › Press Release ● Major
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
businesswire.com • 5mo ago Press Release ● Major ⚠ 1
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Ironwood Pharmaceuticals reported a strong first quarter with total revenue of $106.5 million, up 159% year-over-year, driven primarily by a 97% surge in LINZESS U.S. net sales to $272.5 million.
The company swung to a GAAP net income of $40.8 million, or $0.24 per share, compared to a net loss in the prior year, and maintained its full-year 2026 financial guidance.
Pipeline progress includes a May 24 PDUFA date for a LINZESS pediatric sNDA and the planned initiation of a Phase 3 confirmatory trial for apraglutide in the second quarter.
• 5mo ago AI analysis › Press Release
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Ironwood presented survey findings at DDW 2026 highlighting HCP prioritization of reducing TPN days and volume for SBS patients, alongside long-term safety data for its GLP-2 analog apraglutide.
The LANDMARK survey of 336 HCPs found reducing TPN days per week is the top priority for future therapies, aligning with endpoints in the ongoing STARS and planned STARS-2 trials.
Pooled data from the STARS clinical program showed apraglutide maintained a well-tolerated long-term safety profile with low discontinuation rates.
• 5mo ago AI analysis › Press Release
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Ironwood Pharmaceuticals announced it will present data highlighting the burden of total parenteral nutrition in Short Bowel Syndrome (SBS) at the Digestive Disease Week 2026 meeting.
The company will also feature long-term safety and tolerability data from the STARS clinical trial program for apraglutide, alongside multiple analyses of LINZESS (linaclotide) efficacy and safety in IBS-C, CIC, and pediatric populations.
Management estimates that approximately 18,000 adult patients across the U.S., Europe, and Japan suffer from SBS with intestinal failure, underscoring the significant unmet need for new therapies.
• 6mo ago AI analysis › 
